NCT02012218

Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy

A Phase 3b, Multicenter, Open-label Exploratory Trial to Evaluate the Efficacy, Safety, and Subject Satisfaction With Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 61 (actual)
• Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The objectives of this exploratory trial are to evaluate the efficacy, safety, and subjects' subjective satisfaction when switching to adjunctive brexpiprazole in subjects with MDD who have responded inadequately to preceding adjunctive drug therapy.

Conditions

• Major Depressive Disorder (MDD)

Interventions

Type	Name	Description
DRUG	ADT
DRUG	Brexpiprazole

Timeline

• Start date: 2013-11-01
• Primary completion: 2014-10-01
• Completion: 2014-10-01
• First posted: 2013-12-16
• Last updated: 2015-12-29
• Results posted: 2015-10-08

Locations

24 sites across 1 country: United States